Amvuttra (vutisiran) and Onpattro (patisiran) now listed on PBS

Both Amvuttra (vutisiran) and Onpattro (patisiran) are now listed on the PBS for treatment of hereditary ATTR amyloidosis with neuropathy 

The vutrisiran medicare PBS (Medicare) program opened for patients with hereditary transthyretin amyloidosis with neuropathy on 1^st May.

Vutrisiran is a genetic medicine that acts similarly to patisiran to reduce the production of transthyretin amyloidosis. It is just as effective as patisiran in treating those with hereditary transthyretin amyloidosis (ATTRv) with neuropathy. Vutrisiran is administered via subcutaneous injection (injection under the skin in the belly) every three months, while patisiran is administered intravenously (through a drip) every three weeks. Patients who are currently receiving patisiran on the Medicare program can now switch over to the vutrisiran Medicare program. From now on, newly diagnosed patients with ATTRv with neuropathy who fulfill the Medicare eligibility requirements can start directly on vutrisiran.